A practical reference on As-needed dosing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
=== Basement membrane === The basal surface of epithelial tissue rests on a basement membrane and the free/apical surface faces body fluid or outside. The basement membrane acts as a scaffolding on which epithelium can grow and regenerate after injuries. Epithelial tissue has a nerve supply, but no blood supply and must be nourished by substances diffusing from the blood vessels in the underlying tissue. The basement membrane acts as a selectively permeable membrane that determines which substances will be able to enter the epithelium. The basal lamina is made up of laminin (glycoproteins) secreted by epithelial cells. The reticular lamina beneath the basal lamina is made up of collagen proteins secreted by connective tissue.
The ancient Indian sexual treatise Kama Sutra, written in Sanskrit, probably between the second and fourth centuries AD, divides men into three classes based on penis size: "hare" size (about 5–7 cm, or 2–3 inches, when erect), "bull" size (10–15 cm, or 4–6 inches), and "horse" size (18–20 cm, or 7–8 inches). The treatise also divides women's vaginas into three sizes ("deer", "mare", and "elephant") and advises that a man match the size of the vagina of the woman he is having sex with to the size of his own penis. It also gives medically dubious advice on how to enlarge one's penis using wasp stings.
Medical personnel were routinely deployed as formed units and individual augmentees since the start of operations in Iraq and, since 2003, Reserves provided over 40% of the hospital-based personnel for operations in Afghanistan and provided the 'lead unit' for 50% of the operational tours. By 2011, across Iraq and Afghanistan, a number of reservists had been decorated and 27 had given their lives.
=== Cancer === Because MTs play an important role in transcription factor regulation, defects in MT function or expression may lead to malignant transformation of cells and ultimately cancer. Studies have found increased expression of MTs in some cancers of the breast, colon, kidney, liver, skin (melanoma), lung, nasopharynx, ovary, prostate, mouth, salivary gland, testes, thyroid and urinary bladder; they have also found lower levels of MT expression in hepatocellular carcinoma and liver adenocarcinoma. Evidence suggests that greater MT expression may cause resistance to chemotherapy.
N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.
Sources: en.wikipedia.org
Aberrant basal cell carcinoma Acanthoma fissuratum (granuloma fissuratum, spectacle frame acanthoma) Acrospiroma (clear cell hidradenoma, dermal duct tumor, hidroacanthoma simplex, nodular hidradenoma, poroma) Actinic keratosis (senile keratosis, solar keratosis) Adenoid squamous cell carcinoma (pseudoglandular squamous cell carcinoma) Aggressive digital papillary adenocarcinoma (digital papillary adenocarcinoma, papillary adenoma) Apocrine gland carcinoma Apocrine nevus Arsenical keratosis Atrophic actinic keratosis Balanitis plasmacellularis (balanoposthitis chronica circumscripta plasmacellularis, balanitis circumscripta plasmacellularis, plasma cell balanitis, plasma cell vulvitis, vulvitis circumscripta plasmacellularis, Zoon's balanitis, Zoon's erythroplasia, Zoon's vulvitis) Basal cell carcinoma Basaloid follicular hamartoma Basaloid squamous cell carcinoma Birt–Hogg–Dubé syndrome Bowen's disease (squamous cell carcinoma in situ) Brooke–Fordyce syndrome Ceruminoma Cicatricial basal cell carcinoma (morpheaform basal cell carcinoma, morphoeic basal cell carcinoma) Ciliated cyst of the vulva (cutaneous Müllerian cyst, paramesonephric mucinous cyst of the vulva) Clear cell acanthoma (acanthome cellules claires of Degos and Civatte, Degos acanthoma, pale cell acanthoma) Clear cell squamous cell carcinoma (clear cell carcinoma of the skin) Chronic scar keratosis (chronic cicatrix keratosis) Clonal seborrheic keratosis Common seborrheic keratosis (basal cell papilloma, solid seborrheic keratosis) Cowden syndrome (Cowden's disease, multiple hamartoma syndrome) Cutaneous ciliated cyst Cutaneous columnar cyst Cutaneous horn (Cornu cutaneum) Cystic basal cell carcinoma Dermal eccrine cylindroma (cylindroma) Dermatosis papulosa nigra Desmoplastic trichoepithelioma Dilated pore (dilated pore of Winer) Eccrine carcinoma (syringoid carcinoma) Eccrine nevus Epidermal cyst (epidermal inclusion cyst, epidermoid cyst, infundibular cyst, keratin cyst) Epidermal nevus syndrome (Feuerstein and Mims syndrome, Solomon's syndrome) Epidermolytic acanthoma Epithelioma cuniculatum (Ackerman tumor, carcinoma cuniculatum) Eruptive vellus hair cyst Erythroplasia of Queyrat Extramammary Paget's disease Fibroepithelioma Fibroepithelioma of Pinkus Fibrofolliculoma Follicular hybrid cyst (Hybrid cyst) Folliculosebaceous-apocrine hamartoma (follicular-apocrine hamartoma) Folliculosebaceous cystic hamartoma Generalized eruptive keratoacanthoma (generalized eruptive keratoacanthoma of Grzybowski) Giant solitary trichoepithelioma Hidradenoma Hidradenocarcinoma Hidrocystoma (cystadenoma, Moll's gland cyst, sudoriferous cyst) Hydrocarbon keratosis (pitch keratosis, tar keratosis, tar wart) Hyperkeratosis lenticularis perstans (Flegel's disease) Hyperkeratosis of the nipple and areola Hyperkeratotic actinic keratosis Ichthyosis hystrix (ichthyosis hystrix gravior type Lambert, porcupine man, systematized verrucous nevus) Ichthyosis hystrix of Curth–Macklin Infiltrative basal cell carcinoma Inflammatory linear verrucous epidermal nevus Inverted follicular keratosis Irritated seborrheic keratosis (basosquamous cell acanthoma, inflamed seborrheic keratosis) Isthmicoma (infundibuloma, tumor of the follicular infundibulum) Juvenile myelomonocytic leukemia Keratin implantation cyst Keratoacanthoma Keratoacanthoma centrifugum marginatum Large cell acanthoma Lichenoid actinic keratosis Lichenoid keratosis (benign lichenoid keratosis, lichen planus-like keratosis, solitary lichen planus, solitary lichenoid keratosis) Linear verrucous epidermal nevus (linear epidermal nevus, verrucous epidermal nevus) Malignant acrospiroma (spiradenocarcinoma) Malignant mixed tumor (malignant chondroid syringoma) Malignant trichilemmal cyst Mantleoma Marjolin's ulcer Melanoacanthoma (pigmented seborrheic keratosis) Merkel cell carcinoma (cutaneous apudoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, trabecular carcinoma of the skin) Microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) Micronodular basal cell carcinoma Milia en plaque Milium Mixed tumor (chondroid syringoma) Mucinous carcinoma Mucinous nevus (nevus mucinosus) Muir–Torre syndrome Multiple familial trichoepithelioma (Brooke–Spiegler syndrome, epithelioma adenoides cysticum) Multiple keratoacanthomas (Ferguson–Smith syndrome, Ferguson-Smith type of multiple self-healing keratoacanthomas, multiple keratoacanthomas of the Ferguson–Smith type) Multiple minute digitate hyperkeratosis (digitate keratoses, disseminated spiked hyperkeratosis, familial disseminated piliform hyperkeratosis, minute aggregate keratosis) Nevoid basal cell carcinoma syndrome (basal cell nevus syndrome, Gorlin syndrome, Gorlin–Goltz syndrome) Nevus comedonicus (comedo nevus) Nevus comedonicus syndrome Nevus sebaceous (nevus sebaceous of Jadassohn, organoid nevus) Nevus unius lateris Nodular basal cell carcinoma (classic basal cell carcinoma) Paget's disease of the breast Papillary eccrine adenoma (tubular apocrine adenoma) Papillary hidradenoma (hidradenoma papilliferum) Papillomatosis cutis carcinoides (Gottron's carcinoid papillomatosis, papillomatosis cutis carcinoides of Gottron–Eisenlohr) Patch blue nevus (acquired dermal melanocytosis, dermal melanocyte hamartoma) Perifollicular fibroma Phakomatosis pigmentokeratotica Pigmented actinic keratosis Pigmented basal cell carcinoma Pigmented hairy epidermal nevus syndrome Pilar sheath acanthoma Pilonidal sinus (Barber's interdigital pilonidal sinus, pilonidal cyst, pilonidal disease) Porocarcinoma (malignant poroma, eccrine porocarcinoma) Polypoid basal cell carcinoma Pore-like basal cell carcinoma Primary cutaneous adenoid cystic carcinoma Proliferating epidermoid cyst (proliferating epithelial cyst) Proliferating trichilemmal cyst (pilar tumor, proliferating follicular cystic neoplasm, proliferating pilar tumor, proliferating trichilemmal tumor) Pseudocyst of the auricle (auricular endochondrial pseudocyst, cystic chondromalacia, endochondral pseudocyst, intracartilaginous cyst) Pseudoepitheliomatous keratotic and micaceous balanitis PUVA keratosis Rasmussen syndrome Reactional keratosis Reticulated seborrheic keratosis (adenoid seborrheic keratosis) Rodent ulcer (Jacobi ulcer) Schimmelpenning syndrome (Schimmelpenning–Feuerstein–Mims syndrome) Sebaceoma (sebaceous epithelioma) Sebaceous adenoma Sebaceous carcinoma Sebaceous hyperplasia Sebaceous nevus syndrome Seboacanthoma Seborrheic keratosis (seborrheic verruca, senile wart) Seborrheic keratosis with squamous atypia Signet-ring cell squamous cell carcinoma Solitary keratoacanthoma (subungual keratoacanthoma) Solitary trichoepithelioma Spindle cell squamous cell carcinoma (spindle cell carcinoma) Spiradenoma Squamous cell carcinoma Steatocystoma multiplex (epidermal polycystic disease, sebocystomatosis) Steatocystoma simplex (simple sebaceous duct cyst, solitary steatocystoma) Stucco keratosis (digitate seborrheic keratosis, hyperkeratotic seborrheic keratosis, keratosis alba, serrated seborrheic keratosis, verrucous seborrheic keratosis) Superficial basal cell carcinoma (superficial multicentric basal cell carcinoma) Syringadenoma papilliferum (syringocystadenoma papilliferum) Syringofibroadenoma (acrosyringeal nevus of Weedon and Lewis) Syringoma Systematized epidermal nevus Thermal keratosis Trichilemmal carcinoma Trichilemmal cyst (isthmus-catagen cyst, pilar cyst) Trichilemmoma Trichoadenoma (trichoadenoma of Nikolowski) Trichoblastoma Trichoblastic fibroma Trichodiscoma Trichofolliculoma Unilateral palmoplantar verrucous nevus Urethral caruncle Verrucous carcinoma Verrucous cyst (cystic papilloma) Viral keratosis Warty dyskeratoma (isolated dyskeratosis follicularis) Waxy keratosis of childhood (kerinokeratosis papulosa) Zoon's vulvitis Zosteriform speckled lentiginous nevus
=== Focused shockwave therapy === Focused shockwave therapy involves passing short, high frequency acoustic pulses through the skin and into the penis. These waves break down any plaques within the blood vessels, encourage the formation of new vessels, and stimulate repair and tissue regeneration. Focused shockwave therapy appears to work best for males with vasculogenic ED, which is a blood vessel disorder that affects blood flow to tissue in the penis. The treatment is painless and has no known side effects. Treatment with shockwave therapy can lead to a significant improvement of the IIEF (International Index of Erectile Function).
=== Gott ist schön (dissertation 1998) === In his dissertation Gott ist schön (God is Beautiful), which focuses on reception aesthetics and philology, Kermani shows how prominently Islamic tradition perceives the aesthetic dimension of the Koran. The Koran is described as a beguiling, captivating work of art, its beauty capturing people's hearts with an irresistible appeal. The beauty and clarity of the Koran is thus proof of its divine inspiration. According to this conception, God communicates in the Koran in an aesthetically mediated way in hopes to be understood accordingly by those whom the Koran addresses. If God seeks understanding recognition rather than blind obedience, he must encounter receptive people in an aesthetic way. For—at least according to Navid Kermani's thesis informed by his analytical view of Islamic tradition—religious recognition in Islam is conveyed aesthetically as the thrilling, goose bump-inducing hearing of a language described as beautiful, i.e. as an experience of beauty. Kermani is therefore concerned with appreciating the power of aesthetics on a religious level. He views this mystical insight as being entirely in line with the more recent Western aesthetics since Hegel. In almost all philosophical theories of art in the modern tradition, aesthetic experience is about truth. Indeed, contrary to Kant, aesthetic experience need not be about enjoyment or disinterested pleasure. It may simply be about discovering the truth, whatever the cost.
Prior to its inclusion in newborn screening, short-chain acyl-CoA dehydrogenase deficiency (SCADD) was thought to be life-threatening. Most patients identified via newborn screening as having this enzyme deficiency were asymptomatic, to the extent that SCADD was removed from screening panels in a number of regions. Without the cohort of patients identified by newborn screening, this clinical phenotype would likely not have been identified.
==== United Kingdom ==== On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)". The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexylamines, including 3-MeO-PCP.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.